Management of acute vertigo with betahistine

This open, prospective study was carried out in 29 outpatients of vertigo with Betahistine treatment at a dose of 16 mg three times daily far a maximum treatment period of 6 weeks or earlier until remission of vertigo attacks. The evaluations were carried out based on three parameters such as frequency, duration, and severity of vertigo attacks. Betahistino showed a significant improvement in the three parameters of frequency, duration and severity of vertigo attacks. Associated symptoms such as tinnitus, nausea, vomiting, headache, faintness showed a significant improvement with the therapy. Subgroup analysis showed a significant improvement of patients with severe and incapacitating verlign attaeks at baseline. Thus, this study proves excellent efficacy and goad tolerability of Betahistine as an anti-vertigo drug at a dose of 16 mg three times daily and gives a new insight for controlling acute or severe vertigo attacks without causing sedation.